Deshpande Anagha, Munoz Javier, Kelemen Katalin, Dabak Vrushali, Hanbali Amr, Kurzrock Razelle
Mayo Clinic Alix School of Medicine, Scottsdale, AZ, USA.
Department of Hematology, Mayo Clinic Arizona, Phoenix, AZ, USA.
J Immunother Precis Oncol. 2022 Dec 27;6(1):56-58. doi: 10.36401/JIPO-22-22. eCollection 2023 Feb.
Primary splenic or hepatic angiosarcomas are ultra-rare and aggressive malignancies associated with poor prognosis. The mainstay treatments are surgical resection and chemotherapy. We report a case of angiosarcoma in a 50-year-old woman who presented with bruising, fatigue, ecchymosis, and hepatosplenomegaly. She was treated with the multi-kinase inhibitor sunitinib for 4 weeks before developing a splenic hemorrhage and succumbing. Recent studies have demonstrated the clinical benefit of immunotherapies in angiosarcomas. Additionally, sequencing techniques have showcased the diverse molecular aberrations involved in angiosarcomas, which offer opportunities for precision-matched targeted therapies such as inhibitors of the VEGF/VEGFR axis and PI3K/Akt/mTor pathway.
原发性脾脏或肝脏血管肉瘤极为罕见且具有侵袭性，预后较差。主要治疗方法是手术切除和化疗。我们报告一例50岁女性血管肉瘤患者，该患者出现瘀斑、疲劳、瘀点和肝脾肿大。她接受多激酶抑制剂舒尼替尼治疗4周后出现脾脏出血并死亡。最近的研究表明免疫疗法对血管肉瘤有临床益处。此外，测序技术展示了血管肉瘤中涉及的多种分子异常，这为精准匹配的靶向治疗提供了机会，如VEGF/VEGFR轴抑制剂和PI3K/Akt/mTor通路抑制剂。
